Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Vaginal And Vulval Inflammatory Diseases Treatment Market Snapshot (2023 To 2033)

The global vaginal and vulval inflammatory diseases treatment market is expected to be worth US$ 2.96 Billion in the fiscal year 2023, which rose up from US$ 2.8 Billion in the fiscal year 2022. From 2023 to 2033, the global market is expected to grow at a steady 5.8% CAGR, reaching a value of US$ 5.21 Billion by the end of 2033.

Both vulvitis (vulval inflammation) and vaginitis (vaginal inflammation) refer to inflammation of the female reproductive organs. Vulvitis is an infection of the genitals, or vulva - the outermost portion of the female reproductive anatomy. Vaginitis is an inside-the-body inflammation that damages the vagina. Vulvovaginitis is an inflammation that affects both the vulva and the vagina. These inflammatory disorders are typically brought on by yeast, candida species, or candida Albicans. Atypical vaginal discharge, dyspareunia, external dysuria, vaginal discomfort, and pruritis are a few signs of vaginal and vulval inflammation.

Approximately 75% of women are expected to have vaginal and vulval inflammation at least once, and 42% to 45% of women may experience the illness twice or more, according to statistics from the Centers for Disease Control and Prevention. Depending on the clinical presentation, the microbiology, the host characteristics, and the response to treatment, this illness is categorized as difficult or simple.

In most cases, the problem necessitates consulting a gynecologist or simply a nurse practitioner. Antifungal drugs can be used to diagnose and treat vaginal and vulval irritation. Although vaginal and vulval inflammation may usually be managed in a few days, more serious instances may require extended periods of therapy. Such factors have been boosting the treatment market for vaginal and vulval inflammations during the forecast period.

Attributes Details
Expected Market Value (2023) US$ 2.96 Billion
Projected Forecast Value (2033) US$ 5.21 Billion
Global Growth Rate (2023 to 2033) 5.8%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 To 2022 Vaginal And Vulval Inflammatory Diseases Treatment Market Demand Analysis Vs. Forecast 2023 To 2033

The global vaginal and vulval inflammatory diseases treatment market grew at a CAGR of 5.2% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence. These kinds of diseases are quite common among the female population.

One of the main drivers of this market is the increasing cases of diabetic patients along with other infections such as yeast infections and STDs. Such infections spread quickly in the vulval and vaginal region, causing them to swell and develop irritation. Such rising cases have been propelling the market for the treatment of vaginal and vulvar diseases from 2023 to 2033.

As a result, the global vaginal and vulval inflammatory diseases treatment market is expected to forecast a CAGR of over 5.5% from 2023 to 2033.

Prominent Growth Drivers Influencing Vaginal And Vulval Inflammatory Diseases Treatment Market

Increasing the incidence of diabetes to boost the demand

A major reason for the occurrence of various kinds of vaginal and vulval inflammation is diabetes, particularly in Type 1 diabetic patients. All across the world, diabetes is becoming more and more common. According to WHO figures, there were around 109 million diabetic patients in 1980; by 2021, that number had increased to 822 million. Compared to high-income countries, the incidence has been increasing more quickly in low- and middle-income countries.

One of the causes of several significant problems, including vaginal itchiness, burning, and infection, is diabetes. About 8.7% of American individuals over the age of 18 had diabetes in 2020. The incidence of vaginal and vulval inflammatory illnesses is expected to rise along with the prevalence of diabetes worldwide. The market for treating vaginal and vulval inflammatory illnesses would rise as a result in the near future.

Increasing government initiatives and R&D to accelerate the growth

Many governmental and non-governmental groups, like the European Institute of Women's Health (EIWH) and Women's Health Organization, have launched campaigns to raise awareness of women's sexual health. The changing lifestyle patterns of women throughout the world, such as drinking and smoking use, and ongoing research and development efforts by various firms are the main drivers of market expansion.

Also, scientists were given funding by the National Institute of Allergy and Infectious Diseases (NIAID) to design the yeast infection test so that the right anti-fungal therapy could be given. Additionally, researchers from the Division of Intramural Population Health Research (DIPHR) at the NICHD are examining a variety of associations between bacterial vaginosis and pregnancy outcomes utilizing both previously collected and recently generated data. As a result, it is anticipated that further research and development will be done for precise diagnosis and boost the global market growth.

What Could Possibly Hinder Vaginal And Vulval Inflammatory Diseases Treatment Market Demand?

Side effects of a few medicines impede the global market

Antifungal drugs, including fluconazole, are used to treat candida infections such as vulvovaginal candidiasis as well as other vulval inflammatory diseases. Fluconazole can interact with many other blood thinners, sedatives, antibiotics, antiseizure drugs, diuretics, and other medicines. Furthermore, different warnings on the medicines are applied to those who have liver illnesses or other ailments that might lead to the negative effect of consuming such circumstances. Thus, such factors can impede the growth of this market and hence curtail the demand for the treatment of vaginal and vulval inflammatory diseases.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Region-wise Analysis

What is the outlook of the North American vaginal and vulval inflammatory diseases treatment market?

The rising incidence of STDs along with other vaginal diseases will boost the growth

North America is predicted to hold the dominant market share of 53% revenue share in 2023 and is the fastest-growing market for vaginal and vulval inflammatory disease treatment, with a dominant 6.4% CAGR from 2023 to 2033.

This predominance is primarily caused by rising rates of polycystic ovary syndrome, menopausal disorders, uterine fibroids, trichomoniasis, endometriosis, HIV/AIDS, etc. among women in the USA, which generates the highest amount of revenue in the region, as a result of changes in lifestyles and an increase in stress. For instance, the Centers for Disease Control and Prevention (CDC) reported in April 2022 that STDs continue to be a major public health problem in the nation. The study was titled Sexually Transmitted Disease Surveillance, 2020.

The same report says that with a number of 1,579,875 reported incidents to the CDC in 2020, Chlamydia trachomatis illness was the most common notifiable sexually transmitted infection in the USA. Infections with 677,869 distinct gonorrhea strains were reported to the CDC in 2020. Such increasing cases have resulted in various types of vaginal and vulval inflammatory diseases. Hence, during the forecast period, the North American region can be expected to show a significant growth rate.

What can be expected from the Asia Pacific market for vaginal and vulval inflammatory disease treatment?

The presence of major players and the rising incidence of diabetes accelerate the growth

During the forecast period, the Asia Pacific market for vaginal and vulval inflammatory disease treatment is expected to garner a steady CAGR of 5.8%. The dominance of the region within this industry is mostly due to the presence of companies like Pfizer Inc., Johnson & Johnson Services Inc., and others.

Additionally, the regional market is growing as a result of the region's increasing diabetes prevalence, which might result in a rise in the incidence of vaginal and vulval inflammatory illnesses in Asian countries. Asians have a significant ethnic and genetic propensity to diabetes, as well as lower risk variable thresholds. As a consequence, they develop diabetes at a relatively young age and have a lower BMI and waist circumference than the Western population. Such factors lead to the growth of various vaginal inflammatory diseases among women. Hence, factors such as these are expected to accelerate the growth in the market from 2023 to 2033.

Category-wise Insights

Which indication segment is expected to gain traction from 2023 to 2033?

The vaginal burning segment will gain the dominant market share

Over the course of the forecast period, the vaginal burning segment by indication type is anticipated to occupy a significant share of the global vaginal and vulval inflammatory disease treatment market. In 2023, this category is anticipated to dominate with a 53% revenue share.

These conditions appear as the microorganism gets in touch with the vagina and causes the area to swell up immediately, with extreme itching and burning sensations. Almost 8 out of 15 women have reported vaginal burning to be the primary symptom of vaginal and vulval inflammation diseases. Such factors are expected to accelerate the growth prospects for vaginal and vulval inflammatory disease treatment from 2023 to 2033.

Which end-user segment is expected to gain traction from 2023 to 2033?

The specialty clinics segment will demand during the forecast period

According to the research by Future Market Insights, the specialty clinic segments will gain popularity during the forecast period. It is anticipated that this segment will occupy a global market share of 25% from 2023 to 2033.

During a case of vaginal and vulval inflammation, patients prefer visiting a gynecologist at any clinic or nursing home meant only for women's sexual and reproductive health. This is mainly because the patients get a lot of options for the doctors to choose from and the same goes for their treatments as well. Hence, factors such as these are expected to propel the market growth during the forecast period.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Start-up Scenario

The goal of the newly established firms in this industry is to apply a variety of methods, including the introduction of new goods and acquisitions, to strengthen their market positions globally. Additionally, a sharp increase in the amount of public financing available for the development of these medications is anticipated to fuel the market.

Another American femtech firm, Evvy, has entered the competition to collect data sets to aid in identifying and researching a variety of health conditions that might impact women. Evvy introduced an at-home test kit for the vaginal microbiota in 2022. The user sends their swab back to the business for processing, where they receive thorough details and assessment of the microorganisms (fungi and bacteria) prevalent in their vagina and potentially linked to a range of health issues or inflammations.

Competitive Landscape

Some of the prominent players in the global market for vaginal and vulval inflammatory diseases treatment are:

  • Almirall
  • VenusConcept
  • ThermiGen LLC
  • Lutronic
  • BTL Group of Companies
  • Viveve
  • Fotona
  • Evofem Biosciences, Inc.
  • Spero Therapeutics
  • Hologic
  • Kyung Hee University Hospital

Some of the prominent developments of the key players in the market are:

  • Evofem Biosciences, Inc. presented additional results from the Phase 3 EMPOWER clinical study of Phexxi (lactic acid, citric acid, and potassium bitartrate) in May 2022, revealing that women who participated in the EMPOWER trial had fewer urinary tract infections (UTIs) than the general population. In order to fill immediate needs in women's reproductive and sexual health, Evofem Biosciences, Inc. is creating and marketing novel solutions, such as hormone-free, woman-controlled contraception and gonorrhea and chlamydia protection. Phexxi® (lactic acid, citric acid, and potassium bitartrate), the company's first FDA-approved medication, is a hormone-free, prescription-only vaginal gel contraception.
  • The US Food and Drug Administration (USFDA) approved Priority Review for Spero Therapeutics' tebipenem HBr (tebipenem pivoxil hydrobromide) New Drug Registration in January 2022 for the therapy of individuals with complex urinary tract infections (cUTI) as well as inflammations, especially pyelonephritis, caused by sensitive bacteria.

Report Scope

Report Attribute Details
Growth Rate CAGR of 5.8% from 2023 to 2033
Market value in 2023 US$ 2.96 Billion
Market value in 2033 US$ 5.21 Billion
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units USD Billion for Value
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Indication
  • Treatment
  • End-user
  • Region
Regions Covered
  • North America
  • Latin America
  • Asia Pacific
  • Oceania
  • Middle East & Africa
Key Countries Profiled
  • United States of America
  • Canada
  • Mexico
  • Brazil
  • Germany
  • Italy
  • France
  • United Kingdom
  • Spain
  • Poland
  • Russia
  • China
  • India
  • ASIAN
  • Australia
  • New Zealand
  • Japan
  • GCC Countries
  • South Africa
  • Northern Africa
Key Companies Profiled
  • Almirall
  • VenusConcept
  • ThermiGen LLC
  • Lutronic
  • BTL Group of Companies
  • Viveve
  • Fotona
  • Hologic
  • Kyung Hee University Hospital
Customisation Scope Available on Request

Key Segments Covered In The Vaginal And Vulval Inflammatory Diseases Treatment Market Report

Vaginal And Vulval Inflammatory Diseases Treatment Market By Indication:

  • Vaginal Dryness
  • Vaginal Burning
  • Vaginal Discharge
  • Genital Itching
  • Recurrent Urinary Tract Infections
  • Urinary Incontinence
  • Others

Vaginal And Vulval Inflammatory Diseases Treatment Market By Treatment:

  • Anti-Itch Medications
  • Corticosteroid Ointments
  • Anti-Itch Emollients

Vaginal And Vulval Inflammatory Diseases Treatment Market By End User:

  • Hospital Pharmacies
  • Specialty Clinics
  • Others

Vaginal and Vulval Inflammatory Diseases Treatment Market By Region:

  • North America
  • Latin America
  • Asia Pacific
  • Europe
  • Middle East & Africa (MEA)

Frequently Asked Questions

What is the Market Value in 2023?

A market value of US$ 2.96 billion is projected for 2023.

What is the Projected Growth Rate in North America?

In 2033, North America is predicted to generate a CAGR of 6.4%.

What will the Market Size be in 2033?

By 2033, the market is expected to reach US$ 5.21 billion.

Which Indication Segment is Expected to Dominate the Market?

The vaginal burning market is to account for 53% of revenue in 2023.

How will the Asia Pacific Market Perform in 2023?

The Asia Pacific region is growing at a steady rate of 5.8% between 2023 and 2033.

Table of Content

1. Executive Summary | Vaginal and Vulval Inflammatory Disease Treatment Market

        1.1. Global Market Outlook

        1.2. Demand-side Trends

        1.3. Supply-side Trends

        1.4. Technology Roadmap Analysis

        1.5. Analysis and Recommendations

2. Market Overview

        2.1. Market Coverage / Taxonomy

        2.2. Market Definition / Scope / Limitations

3. Market Background

        3.1. Market Dynamics

            3.1.1. Drivers

            3.1.2. Restraints

            3.1.3. Opportunity

            3.1.4. Trends

        3.2. Scenario Forecast

            3.2.1. Demand in Optimistic Scenario

            3.2.2. Demand in Likely Scenario

            3.2.3. Demand in Conservative Scenario

        3.3. Opportunity Map Analysis

        3.4. Investment Feasibility Matrix

        3.5. PESTLE and Porter’s Analysis

        3.6. Regulatory Landscape

            3.6.1. By Key Regions

            3.6.2. By Key Countries

        3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

        4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

        4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

            4.2.1. Y-o-Y Growth Trend Analysis

            4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication

        5.1. Introduction / Key Findings

        5.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2018 to 2022

        5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2023 to 2033

            5.3.1. Vaginal Dryness

            5.3.2. Vaginal Burning

            5.3.3. Vaginal Discharge

            5.3.4. Genital Itching

            5.3.5. Recurrent Urinary Tract Infections

            5.3.6. Urinary Incontinence

            5.3.7. Others

        5.4. Y-o-Y Growth Trend Analysis By Indication, 2018 to 2022

        5.5. Absolute $ Opportunity Analysis By Indication, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment

        6.1. Introduction / Key Findings

        6.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022

        6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033

            6.3.1. Anti-itch Medications

            6.3.2. Corticosteroid Ointments

            6.3.3. Anti-itch Emollients

        6.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022

        6.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-User 

        7.1. Introduction / Key Findings

        7.2. Historical Market Size Value (US$ Million) Analysis By End-User, 2018 to 2022

        7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-User, 2023 to 2033

            7.3.1. Hospitals

            7.3.2. Specialty Clinics

            7.3.3. Others

        7.4. Y-o-Y Growth Trend Analysis By End-User, 2018 to 2022

        7.5. Absolute $ Opportunity Analysis By End-User, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

        8.1. Introduction

        8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

        8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

            8.3.1. North America

            8.3.2. Latin America

            8.3.3. Europe

            8.3.4. South Asia

            8.3.5. East Asia

            8.3.6. Oceania

            8.3.7. Middle East and Africa (MEA)

        8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

        9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

        9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

            9.2.1. By Country

                9.2.1.1. The USA

                9.2.1.2. Canada

            9.2.2. By Indication

            9.2.3. By Treatment

            9.2.4. By End-User

        9.3. Market Attractiveness Analysis

            9.3.1. By Country

            9.3.2. By Indication

            9.3.3. By Treatment

            9.3.4. By End-User

        9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

        10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

        10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

            10.2.1. By Country

                10.2.1.1. Brazil

                10.2.1.2. Mexico

                10.2.1.3. Rest of Latin America

            10.2.2. By Indication

            10.2.3. By Treatment

            10.2.4. By End-User

        10.3. Market Attractiveness Analysis

            10.3.1. By Country

            10.3.2. By Indication

            10.3.3. By Treatment

            10.3.4. By End-User

        10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

        11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

        11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

            11.2.1. By Country

                11.2.1.1. Germany

                11.2.1.2. The UK

                11.2.1.3. France

                11.2.1.4. Spain

                11.2.1.5. Italy

                11.2.1.6. Rest of Europe

            11.2.2. By Indication

            11.2.3. By Treatment

            11.2.4. By End-User

        11.3. Market Attractiveness Analysis

            11.3.1. By Country

            11.3.2. By Indication

            11.3.3. By Treatment

            11.3.4. By End-User

        11.4. Key Takeaways

12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

        12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

        12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

            12.2.1. By Country

                12.2.1.1. India

                12.2.1.2. Malaysia

                12.2.1.3. Singapore

                12.2.1.4. Thailand

                12.2.1.5. Rest of South Asia

            12.2.2. By Indication

            12.2.3. By Treatment

            12.2.4. By End-User

        12.3. Market Attractiveness Analysis

            12.3.1. By Country

            12.3.2. By Indication

            12.3.3. By Treatment

            12.3.4. By End-User

        12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

        13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

        13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

            13.2.1. By Country

                13.2.1.1. China

                13.2.1.2. Japan

                13.2.1.3. South Korea

            13.2.2. By Indication

            13.2.3. By Treatment

            13.2.4. By End-User

        13.3. Market Attractiveness Analysis

            13.3.1. By Country

            13.3.2. By Indication

            13.3.3. By Treatment

            13.3.4. By End-User

        13.4. Key Takeaways

14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

        14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

        14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

            14.2.1. By Country

                14.2.1.1. Australia

                14.2.1.2. New Zealand

            14.2.2. By Indication

            14.2.3. By Treatment

            14.2.4. By End-User

        14.3. Market Attractiveness Analysis

            14.3.1. By Country

            14.3.2. By Indication

            14.3.3. By Treatment

            14.3.4. By End-User

        14.4. Key Takeaways

15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

        15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

        15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

            15.2.1. By Country

                15.2.1.1. GCC Countries

                15.2.1.2. South Africa

                15.2.1.3. Israel

                15.2.1.4. Rest of MEA

            15.2.2. By Indication

            15.2.3. By Treatment

            15.2.4. By End-User

        15.3. Market Attractiveness Analysis

            15.3.1. By Country

            15.3.2. By Indication

            15.3.3. By Treatment

            15.3.4. By End-User

        15.4. Key Takeaways

16. Key Countries Market Analysis

        16.1. The USA

            16.1.1. Pricing Analysis

            16.1.2. Market Share Analysis, 2022

                16.1.2.1. By Indication

                16.1.2.2. By Treatment

                16.1.2.3. By End-User

        16.2. Canada

            16.2.1. Pricing Analysis

            16.2.2. Market Share Analysis, 2022

                16.2.2.1. By Indication

                16.2.2.2. By Treatment

                16.2.2.3. By End-User

        16.3. Brazil

            16.3.1. Pricing Analysis

            16.3.2. Market Share Analysis, 2022

                16.3.2.1. By Indication

                16.3.2.2. By Treatment

                16.3.2.3. By End-User

        16.4. Mexico

            16.4.1. Pricing Analysis

            16.4.2. Market Share Analysis, 2022

                16.4.2.1. By Indication

                16.4.2.2. By Treatment

                16.4.2.3. By End-User

        16.5. Germany

            16.5.1. Pricing Analysis

            16.5.2. Market Share Analysis, 2022

                16.5.2.1. By Indication

                16.5.2.2. By Treatment

                16.5.2.3. By End-User

        16.6. The UK

            16.6.1. Pricing Analysis

            16.6.2. Market Share Analysis, 2022

                16.6.2.1. By Indication

                16.6.2.2. By Treatment

                16.6.2.3. By End-User

        16.7. France

            16.7.1. Pricing Analysis

            16.7.2. Market Share Analysis, 2022

                16.7.2.1. By Indication

                16.7.2.2. By Treatment

                16.7.2.3. By End-User

        16.8. Spain

            16.8.1. Pricing Analysis

            16.8.2. Market Share Analysis, 2022

                16.8.2.1. By Indication

                16.8.2.2. By Treatment

                16.8.2.3. By End-User

        16.9. Italy

            16.9.1. Pricing Analysis

            16.9.2. Market Share Analysis, 2022

                16.9.2.1. By Indication

                16.9.2.2. By Treatment

                16.9.2.3. By End-User

        16.10. India

            16.10.1. Pricing Analysis

            16.10.2. Market Share Analysis, 2022

                16.10.2.1. By Indication

                16.10.2.2. By Treatment

                16.10.2.3. By End-User

        16.11. Malaysia

            16.11.1. Pricing Analysis

            16.11.2. Market Share Analysis, 2022

                16.11.2.1. By Indication

                16.11.2.2. By Treatment

                16.11.2.3. By End-User

        16.12. Singapore

            16.12.1. Pricing Analysis

            16.12.2. Market Share Analysis, 2022

                16.12.2.1. By Indication

                16.12.2.2. By Treatment

                16.12.2.3. By End-User

        16.13. Thailand

            16.13.1. Pricing Analysis

            16.13.2. Market Share Analysis, 2022

                16.13.2.1. By Indication

                16.13.2.2. By Treatment

                16.13.2.3. By End-User

        16.14. China

            16.14.1. Pricing Analysis

            16.14.2. Market Share Analysis, 2022

                16.14.2.1. By Indication

                16.14.2.2. By Treatment

                16.14.2.3. By End-User

        16.15. Japan

            16.15.1. Pricing Analysis

            16.15.2. Market Share Analysis, 2022

                16.15.2.1. By Indication

                16.15.2.2. By Treatment

                16.15.2.3. By End-User

        16.16. South Korea

            16.16.1. Pricing Analysis

            16.16.2. Market Share Analysis, 2022

                16.16.2.1. By Indication

                16.16.2.2. By Treatment

                16.16.2.3. By End-User

        16.17. Australia

            16.17.1. Pricing Analysis

            16.17.2. Market Share Analysis, 2022

                16.17.2.1. By Indication

                16.17.2.2. By Treatment

                16.17.2.3. By End-User

        16.18. New Zealand

            16.18.1. Pricing Analysis

            16.18.2. Market Share Analysis, 2022

                16.18.2.1. By Indication

                16.18.2.2. By Treatment

                16.18.2.3. By End-User

        16.19. GCC Countries

            16.19.1. Pricing Analysis

            16.19.2. Market Share Analysis, 2022

                16.19.2.1. By Indication

                16.19.2.2. By Treatment

                16.19.2.3. By End-User

        16.20. South Africa

            16.20.1. Pricing Analysis

            16.20.2. Market Share Analysis, 2022

                16.20.2.1. By Indication

                16.20.2.2. By Treatment

                16.20.2.3. By End-User

        16.21. Israel

            16.21.1. Pricing Analysis

            16.21.2. Market Share Analysis, 2022

                16.21.2.1. By Indication

                16.21.2.2. By Treatment

                16.21.2.3. By End-User

17. Market Structure Analysis

        17.1. Competition Dashboard

        17.2. Competition Benchmarking

        17.3. Market Share Analysis of Top Players

            17.3.1. By Regional

            17.3.2. By Indication

            17.3.3. By Treatment

            17.3.4. By End-User

18. Competition Analysis

        18.1. Competition Deep Dive

            18.1.1. Almirall

                18.1.1.1. Overview

                18.1.1.2. Product Portfolio

                18.1.1.3. Profitability by Market Segments

                18.1.1.4. Sales Footprint

                18.1.1.5. Strategy Overview

                    18.1.1.5.1. Marketing Strategy

            18.1.2. VenusConcept

                18.1.2.1. Overview

                18.1.2.2. Product Portfolio

                18.1.2.3. Profitability by Market Segments

                18.1.2.4. Sales Footprint

                18.1.2.5. Strategy Overview

                    18.1.2.5.1. Marketing Strategy

            18.1.3. Alma Lasers

                18.1.3.1. Overview

                18.1.3.2. Product Portfolio

                18.1.3.3. Profitability by Market Segments

                18.1.3.4. Sales Footprint

                18.1.3.5. Strategy Overview

                    18.1.3.5.1. Marketing Strategy

            18.1.4. ThermiGen LLC

                18.1.4.1. Overview

                18.1.4.2. Product Portfolio

                18.1.4.3. Profitability by Market Segments

                18.1.4.4. Sales Footprint

                18.1.4.5. Strategy Overview

                    18.1.4.5.1. Marketing Strategy

            18.1.5. Lutronic

                18.1.5.1. Overview

                18.1.5.2. Product Portfolio

                18.1.5.3. Profitability by Market Segments

                18.1.5.4. Sales Footprint

                18.1.5.5. Strategy Overview

                    18.1.5.5.1. Marketing Strategy

            18.1.6. BTL Group of Companies

                18.1.6.1. Overview

                18.1.6.2. Product Portfolio

                18.1.6.3. Profitability by Market Segments

                18.1.6.4. Sales Footprint

                18.1.6.5. Strategy Overview

                    18.1.6.5.1. Marketing Strategy

            18.1.7. Viveve

                18.1.7.1. Overview

                18.1.7.2. Product Portfolio

                18.1.7.3. Profitability by Market Segments

                18.1.7.4. Sales Footprint

                18.1.7.5. Strategy Overview

                    18.1.7.5.1. Marketing Strategy

            18.1.8. Fotona

                18.1.8.1. Overview

                18.1.8.2. Product Portfolio

                18.1.8.3. Profitability by Market Segments

                18.1.8.4. Sales Footprint

                18.1.8.5. Strategy Overview

                    18.1.8.5.1. Marketing Strategy

            18.1.9. Hologic

                18.1.9.1. Overview

                18.1.9.2. Product Portfolio

                18.1.9.3. Profitability by Market Segments

                18.1.9.4. Sales Footprint

                18.1.9.5. Strategy Overview

                    18.1.9.5.1. Marketing Strategy

            18.1.10. Kyung Hee University Hospital

                18.1.10.1. Overview

                18.1.10.2. Product Portfolio

                18.1.10.3. Profitability by Market Segments

                18.1.10.4. Sales Footprint

                18.1.10.5. Strategy Overview

                    18.1.10.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Indication, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 4: Global Market Value (US$ Million) Forecast by End-User, 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Indication, 2018 to 2033

Table 7: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 8: North America Market Value (US$ Million) Forecast by End-User, 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 10: Latin America Market Value (US$ Million) Forecast by Indication, 2018 to 2033

Table 11: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 12: Latin America Market Value (US$ Million) Forecast by End-User, 2018 to 2033

Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Europe Market Value (US$ Million) Forecast by Indication, 2018 to 2033

Table 15: Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 16: Europe Market Value (US$ Million) Forecast by End-User, 2018 to 2033

Table 17: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 18: South Asia Market Value (US$ Million) Forecast by Indication, 2018 to 2033

Table 19: South Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 20: South Asia Market Value (US$ Million) Forecast by End-User, 2018 to 2033

Table 21: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 22: East Asia Market Value (US$ Million) Forecast by Indication, 2018 to 2033

Table 23: East Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 24: East Asia Market Value (US$ Million) Forecast by End-User, 2018 to 2033

Table 25: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 26: Oceania Market Value (US$ Million) Forecast by Indication, 2018 to 2033

Table 27: Oceania Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 28: Oceania Market Value (US$ Million) Forecast by End-User, 2018 to 2033

Table 29: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 30: MEA Market Value (US$ Million) Forecast by Indication, 2018 to 2033

Table 31: MEA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 32: MEA Market Value (US$ Million) Forecast by End-User, 2018 to 2033

List of Charts

Figure 1: Global Market Value (US$ Million) by Indication, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by End-User, 2023 to 2033

Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 8: Global Market Value (US$ Million) Analysis by Indication, 2018 to 2033

Figure 9: Global Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033

Figure 10: Global Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033

Figure 11: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 12: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 13: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 14: Global Market Value (US$ Million) Analysis by End-User, 2018 to 2033

Figure 15: Global Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033

Figure 16: Global Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033

Figure 17: Global Market Attractiveness by Indication, 2023 to 2033

Figure 18: Global Market Attractiveness by Treatment, 2023 to 2033

Figure 19: Global Market Attractiveness by End-User, 2023 to 2033

Figure 20: Global Market Attractiveness by Region, 2023 to 2033

Figure 21: North America Market Value (US$ Million) by Indication, 2023 to 2033

Figure 22: North America Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 23: North America Market Value (US$ Million) by End-User, 2023 to 2033

Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 28: North America Market Value (US$ Million) Analysis by Indication, 2018 to 2033

Figure 29: North America Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033

Figure 30: North America Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033

Figure 31: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 32: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 33: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 34: North America Market Value (US$ Million) Analysis by End-User, 2018 to 2033

Figure 35: North America Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033

Figure 36: North America Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033

Figure 37: North America Market Attractiveness by Indication, 2023 to 2033

Figure 38: North America Market Attractiveness by Treatment, 2023 to 2033

Figure 39: North America Market Attractiveness by End-User, 2023 to 2033

Figure 40: North America Market Attractiveness by Country, 2023 to 2033

Figure 41: Latin America Market Value (US$ Million) by Indication, 2023 to 2033

Figure 42: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 43: Latin America Market Value (US$ Million) by End-User, 2023 to 2033

Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 48: Latin America Market Value (US$ Million) Analysis by Indication, 2018 to 2033

Figure 49: Latin America Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033

Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033

Figure 51: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 52: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 54: Latin America Market Value (US$ Million) Analysis by End-User, 2018 to 2033

Figure 55: Latin America Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033

Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033

Figure 57: Latin America Market Attractiveness by Indication, 2023 to 2033

Figure 58: Latin America Market Attractiveness by Treatment, 2023 to 2033

Figure 59: Latin America Market Attractiveness by End-User, 2023 to 2033

Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 61: Europe Market Value (US$ Million) by Indication, 2023 to 2033

Figure 62: Europe Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 63: Europe Market Value (US$ Million) by End-User, 2023 to 2033

Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 68: Europe Market Value (US$ Million) Analysis by Indication, 2018 to 2033

Figure 69: Europe Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033

Figure 70: Europe Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033

Figure 71: Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 72: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 73: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 74: Europe Market Value (US$ Million) Analysis by End-User, 2018 to 2033

Figure 75: Europe Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033

Figure 76: Europe Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033

Figure 77: Europe Market Attractiveness by Indication, 2023 to 2033

Figure 78: Europe Market Attractiveness by Treatment, 2023 to 2033

Figure 79: Europe Market Attractiveness by End-User, 2023 to 2033

Figure 80: Europe Market Attractiveness by Country, 2023 to 2033

Figure 81: South Asia Market Value (US$ Million) by Indication, 2023 to 2033

Figure 82: South Asia Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 83: South Asia Market Value (US$ Million) by End-User, 2023 to 2033

Figure 84: South Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 85: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 86: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 87: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 88: South Asia Market Value (US$ Million) Analysis by Indication, 2018 to 2033

Figure 89: South Asia Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033

Figure 90: South Asia Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033

Figure 91: South Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 92: South Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 93: South Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 94: South Asia Market Value (US$ Million) Analysis by End-User, 2018 to 2033

Figure 95: South Asia Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033

Figure 96: South Asia Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033

Figure 97: South Asia Market Attractiveness by Indication, 2023 to 2033

Figure 98: South Asia Market Attractiveness by Treatment, 2023 to 2033

Figure 99: South Asia Market Attractiveness by End-User, 2023 to 2033

Figure 100: South Asia Market Attractiveness by Country, 2023 to 2033

Figure 101: East Asia Market Value (US$ Million) by Indication, 2023 to 2033

Figure 102: East Asia Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 103: East Asia Market Value (US$ Million) by End-User, 2023 to 2033

Figure 104: East Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 105: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 108: East Asia Market Value (US$ Million) Analysis by Indication, 2018 to 2033

Figure 109: East Asia Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033

Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033

Figure 111: East Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 112: East Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 114: East Asia Market Value (US$ Million) Analysis by End-User, 2018 to 2033

Figure 115: East Asia Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033

Figure 116: East Asia Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033

Figure 117: East Asia Market Attractiveness by Indication, 2023 to 2033

Figure 118: East Asia Market Attractiveness by Treatment, 2023 to 2033

Figure 119: East Asia Market Attractiveness by End-User, 2023 to 2033

Figure 120: East Asia Market Attractiveness by Country, 2023 to 2033

Figure 121: Oceania Market Value (US$ Million) by Indication, 2023 to 2033

Figure 122: Oceania Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 123: Oceania Market Value (US$ Million) by End-User, 2023 to 2033

Figure 124: Oceania Market Value (US$ Million) by Country, 2023 to 2033

Figure 125: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 128: Oceania Market Value (US$ Million) Analysis by Indication, 2018 to 2033

Figure 129: Oceania Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033

Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033

Figure 131: Oceania Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 132: Oceania Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 134: Oceania Market Value (US$ Million) Analysis by End-User, 2018 to 2033

Figure 135: Oceania Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033

Figure 136: Oceania Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033

Figure 137: Oceania Market Attractiveness by Indication, 2023 to 2033

Figure 138: Oceania Market Attractiveness by Treatment, 2023 to 2033

Figure 139: Oceania Market Attractiveness by End-User, 2023 to 2033

Figure 140: Oceania Market Attractiveness by Country, 2023 to 2033

Figure 141: MEA Market Value (US$ Million) by Indication, 2023 to 2033

Figure 142: MEA Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 143: MEA Market Value (US$ Million) by End-User, 2023 to 2033

Figure 144: MEA Market Value (US$ Million) by Country, 2023 to 2033

Figure 145: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 148: MEA Market Value (US$ Million) Analysis by Indication, 2018 to 2033

Figure 149: MEA Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033

Figure 150: MEA Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033

Figure 151: MEA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 152: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 153: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 154: MEA Market Value (US$ Million) Analysis by End-User, 2018 to 2033

Figure 155: MEA Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033

Figure 156: MEA Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033

Figure 157: MEA Market Attractiveness by Indication, 2023 to 2033

Figure 158: MEA Market Attractiveness by Treatment, 2023 to 2033

Figure 159: MEA Market Attractiveness by End-User, 2023 to 2033

Figure 160: MEA Market Attractiveness by Country, 2023 to 2033

Recommendations

Healthcare

Vulvovaginal Candidiasis Treatment Market

Published : December 2022

Healthcare

Vaginitis Treatment Drugs Market

Published : July 2022

Explore Healthcare Insights

View Reports

Vaginal and Vulval Inflammatory Disease Treatment Market